

Ch 2
19. (Amended) A pharmaceutical composition [Composition] according to Claim 18 in which each dose unit contains from 0.5 to 50 mg of the polysaccharide [active principle].

Ch 2
20. (Amended) A pharmaceutical [Pharmaceutical] composition [containing a] comprising the polysaccharide [or salt according to Claims 1 to 14] of Claim 1 in combination with another active ingredient selected from the group consisting of an antithrombotic or anticoagulant [active principle] agent, platelet aggregation inhibitor [or] and antagonist of the glycoprotein IIb/IIIa complex.

Ch 2
21. (Amended) A pharmaceutical [Pharmaceutical] composition according to Claim 20 [characterized in that] wherein the [combined active principle] other active ingredient is dipyridamole, aspirin, ticlopidine or clopidogrel.

Ch 3
Please add the following new claims 25-29.

- 25. A method for treating pathologies dependent on a coagulation dysfunction comprising administering the polysaccharide of Claim 1.
- 26. A method of inhibiting growth factors shown by an inhibition of cell proliferation comprising administering the polysaccharide of Claim 1.
- 27. The polysaccharide according to Claim 11 in which the cation is selected from the cations of alkali metals, in particular sodium and potassium.
- 28. The polysaccharide according to Claim 12 in which the cation is selected from the cations of alkali metals, in particular sodium and potassium.
- 29. A method of treating pathologies dependent on a coagulation dysfunction comprising administering to a patient in need of such treatment a polysaccharide according to Claim 14. --

Please cancel claims 22-24.

REMARKS

This application is a continuation under 37 C.F.R. 1.53(b) of prior application Serial No. 09/202,241 and is filed in lieu of a response to the outstanding Office Action mailed April 12, 2000 in said prior application. Pursuant to the Petition under 37 C.F.R. 1.136(a) for a three-

month extension of time to October 12, 2000 filed in application Serial No. 09/202,241 (copy herewith), the instant continuation is timely filed.

The specification is amended to insert a cross-reference to prior copending application Serial No. 09/202,241 which was filed as a 35 U.S.C. 371 application corresponding to PCT/FR97/01048.

The claims are amended to correspond to the claims of prior application Serial No. 09/202,241 as amended by the preliminary amendment filed December 10, 1998 in said application wherein claims 1-21 and 24 were amended to place them in appropriate U.S. claim format; claims 4-12, 16, 20 and 24 were amended to eliminate multiple dependencies, claims 22 and 23 were canceled and new claims 25-28 were added.

In the instant application, applicants have additionally canceled claim 24 and added new claim 29 which claims the method of use of the polysaccharide of claim 14. No new matter is added by the foregoing amendments.

The application as presently amended contains claims 1-21 and 25-29.

Respectfully submitted,



Paul E. Dupont
Reg. No. 27,438

Address:

Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone: (610) 889-6338
Facsimile: (610) 889-8799

10 Oct 2000
Date

In Re Continuation Application
Under 37 C.R.F. 1.53(b) of: DUCHAUSSOY, et al.

Docket No.: IVD 941-2

FOR: **SYNTHETIC POLYSACCHARIDES, METHODS FOR
PREPARING SAME AND PHARMACEUTICAL
COMPOSITIONS CONTAINING SAID
POLYSACCHARIDES**

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EL676471085US

Date of Deposit: October 11, 2000

I hereby certify that the attached Transmittal Letter is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Commissioner for Patents, Box Patent Application, Washington, DC 20231

Paula M. Dickey
Signature